Georgia's Online Cancer Information Center


back

Bile Duct Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Bile Duct Cancer
Cancer Type = Bile Duct Cancer
NCI ID Cancer Type Trial Name
There are currently 7 active Bile Duct Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCT ID
NCT03656536
Protocol IDs
INCB 54828-302
NCI-2019-01725
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Gynecologic Cancers, Ovarian Cancer, Prostate Cancer
NCT ID
NCT04972981
Protocol IDs
ADCT-901-101
NCI-2021-10797
2021-002292-19
4.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCT ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
5.
Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations
Cancer Type
Bile Duct Cancer, Brain & Spinal Cord Tumor
NCT ID
NCT03212274
Protocol IDs
10129
10129
NCI-2017-01182
2000023083
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Liver Cancer / Hepatoblastoma, Solid Tumor, Unknown Primary
NCT ID
NCT04526106
Protocol IDs
RLY-4008-101
NCI-2020-06870
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type
Bile Duct Cancer
NCT ID
NCT03368963
Protocol IDs
Winship4146-17
NCI-2017-01661
IRB00098958
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.